Eidos Therapeutics, a subsidiary of BridgeBio, operates in the healthcare sector, specifically in the research and development of treatments for a rare disease known as Transthyretin (TTR) amyloidosis (ATTR). This disease, which can severely damage the heart and/or nervous system, is currently underdiagnosed and has limited treatment options. Eidos Therapeutics aims to improve the life expectancy and quality of life for patients suffering from ATTR by developing a novel therapeutic.

The company's research focuses on TTR, a protein found in all vertebrates that plays a crucial role in the transport of thyroxine and vitamin A. It is believed to have a role in preserving cognitive function. A form of amyloidosis, ATTR cardiomyopathy (ATTR-CM), is caused by the destabilization of TTR and the subsequent accumulation of misfolded TTR protein in the myocardium, a muscle tissue in the heart. This condition can significantly impair a patient's quality of life and life expectancy.

Eidos Therapeutics' business model revolves around the discovery and development of treatments for ATTR. The company's primary clients are patients suffering from this disease. The company generates revenue through the development and sale of these treatments.

Keywords: Eidos Therapeutics, BridgeBio, healthcare, research and development, Transthyretin (TTR) amyloidosis (ATTR), treatment, novel therapeutic, TTR protein, ATTR cardiomyopathy (ATTR-CM), myocardium.